Costar projects $190M-$210M Q3 2026 adjusted EBITDA while revising 2026 revenue to $3.715B-$3.755B

NeoGenomics anticipates $802M-$806M 2026 revenue as it targets mid-20% NGS growth and adjusts pharma expectations

Omnicom targets 4.5%-5% 2026 organic growth while advancing $900M synergies and completing $5B buyback by Q1 2027

Corning outlines Springboard 20-30-40 plan with 19% sales CAGR and guides Q3 sales to $4.9B-$5.0B

2 Reasons to Sell EFX and 1 Stock to Buy Instead